Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 2
1979 1
1982 2
1985 3
1986 5
1987 3
1988 4
1989 7
1990 5
1991 1
1992 3
1993 4
1994 5
1995 5
1996 12
1997 10
1998 8
1999 4
2000 8
2001 6
2002 3
2003 5
2004 8
2005 9
2006 12
2007 10
2008 14
2009 22
2010 8
2011 8
2012 7
2013 13
2014 13
2015 5
2016 6
2017 10
2018 12
2019 14
2020 8
2021 17
2022 9
2023 16
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

306 results

Results by year

Filters applied: . Clear all
Page 1
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.
Cordoba S, Onuoha S, Thomas S, Pignataro DS, Hough R, Ghorashian S, Vora A, Bonney D, Veys P, Rao K, Lucchini G, Chiesa R, Chu J, Clark L, Fung MM, Smith K, Peticone C, Al-Hajj M, Baldan V, Ferrari M, Srivastava S, Jha R, Arce Vargas F, Duffy K, Day W, Virgo P, Wheeler L, Hancock J, Farzaneh F, Domning S, Zhang Y, Khokhar NZ, Peddareddigari VGR, Wynn R, Pule M, Amrolia PJ. Cordoba S, et al. Among authors: farzaneh f. Nat Med. 2021 Oct;27(10):1797-1805. doi: 10.1038/s41591-021-01497-1. Epub 2021 Oct 12. Nat Med. 2021. PMID: 34642489 Free PMC article. Clinical Trial.
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.
Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, Albon SJ, Casanovas-Company J, Castro F, Popova B, Villanueva K, Yeung J, Vetharoy W, Guvenel A, Wawrzyniecka PA, Mekkaoui L, Cheung GW, Pinner D, Chu J, Lucchini G, Silva J, Ciocarlie O, Lazareva A, Inglott S, Gilmour KC, Ahsan G, Ferrari M, Manzoor S, Champion K, Brooks T, Lopes A, Hackshaw A, Farzaneh F, Chiesa R, Rao K, Bonney D, Samarasinghe S, Goulden N, Vora A, Veys P, Hough R, Wynn R, Pule MA, Amrolia PJ. Ghorashian S, et al. Among authors: farzaneh f. Nat Med. 2019 Sep;25(9):1408-1414. doi: 10.1038/s41591-019-0549-5. Epub 2019 Sep 2. Nat Med. 2019. PMID: 31477906 Clinical Trial.
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
Roddie C, Dias J, O'Reilly MA, Abbasian M, Cadinanos-Garai A, Vispute K, Bosshard-Carter L, Mitsikakou M, Mehra V, Roddy H, Hartley JA, Spanswick V, Lowe H, Popova B, Clifton-Hadley L, Wheeler G, Olejnik J, Bloor A, Irvine D, Wood L, Marzolini MAV, Domning S, Farzaneh F, Lowdell MW, Linch DC, Pule MA, Peggs KS. Roddie C, et al. Among authors: farzaneh f. J Clin Oncol. 2021 Oct 20;39(30):3352-3363. doi: 10.1200/JCO.21.00917. Epub 2021 Aug 31. J Clin Oncol. 2021. PMID: 34464155 Free PMC article. Clinical Trial.
Cancer Immunotherapy: Whence and Whither.
Stambrook PJ, Maher J, Farzaneh F. Stambrook PJ, et al. Among authors: farzaneh f. Mol Cancer Res. 2017 Jun;15(6):635-650. doi: 10.1158/1541-7786.MCR-16-0427. Epub 2017 Mar 29. Mol Cancer Res. 2017. PMID: 28356330 Free PMC article. Review.
Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study.
Papa S, Adami A, Metoudi M, Beatson R, George MS, Achkova D, Williams E, Arif S, Reid F, Elstad M, Beckley-Hoelscher N, Douri A, Delord M, Lyne M, Shivapatham D, Fisher C, Hope A, Gooljar S, Mitra A, Gomm L, Morton C, Henley-Smith R, Thavaraj S, Santambrogio A, Andoniadou C, Allen S, Gibson V, Cook GJR, Parente-Pereira AC, Davies DM, Farzaneh F, Schurich A, Guerrero-Urbano T, Jeannon JP, Spicer J, Maher J. Papa S, et al. Among authors: farzaneh f. J Immunother Cancer. 2023 Jun;11(6):e007162. doi: 10.1136/jitc-2023-007162. J Immunother Cancer. 2023. PMID: 37321663 Free PMC article.
The strange case of TGN1412.
Farzaneh L, Kasahara N, Farzaneh F. Farzaneh L, et al. Among authors: farzaneh f. Cancer Immunol Immunother. 2007 Feb;56(2):129-34. doi: 10.1007/s00262-006-0189-8. Epub 2006 Jun 17. Cancer Immunol Immunother. 2007. PMID: 16783575 Review. No abstract available.
COVID-19: Time for precision epidemiology.
Koks S, Williams RW, Quinn J, Farzaneh F, Conran N, Tsai SJ, Awandare G, Goodman SR. Koks S, et al. Among authors: farzaneh f. Exp Biol Med (Maywood). 2020 Apr;245(8):677-679. doi: 10.1177/1535370220919349. Epub 2020 Apr 17. Exp Biol Med (Maywood). 2020. PMID: 32301338 Free PMC article. No abstract available.
306 results